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1
Suboxone Treatment for Opioid Abuse in 
Vermont
Within the past 5 years there has been a steady increase in the number of Vermonters seeking 
treatment for opioid and heroin abuse. (1)
While treatment is increasing, fatalities for heroin overdose are also increasing. (1)
From 2010-2015 the number of patients being treated for heroin and opioid abuse in Franklin 
County has increased from 340 to 733. (2)
Methadone and buprenorphine-naloxone (suboxone) treatment are more effective than 
abstinence based programs. (4)
Suboxone treatment is suggested over methadone for socially stable prescription oral opioid 
abuser, with a schedule that does not allow daily methadone clinic visits, or patients with high 
risk of methadone toxicity (elderly patients). (4)
Patient retention rates are higher for methadone treatment than suboxone. (4)
2
Cost Burden for Opioid Abuse 
In 2016 the National Center for Injury Prevention and Control released a study that estimated 
the overall economic burden due to the opioid epidemic within the US to be $78.5 billion (3).
◦ Total spending for health care of the opioid epidemic was $28 billion, which $26 billion was covered by 
insurance
◦ Loss of productivity estimates is $20 billion
◦ Fatal overdose estimates is $21.5 billion





◦ “I’ve struggled with drug addiction for a large part of my life and I can see the toll it has taken on my kids. Two 
of my children have made similar mistakes as I have and I feel guilty about it cause I know it’s my fault. My two 
youngest are 4 and 5 and I can see they are developing nervous habits since I am in and out of their life so 
frequently. Just within the past few months of sticking to being sober I can tell they are calming down. It’s too 
late for my older children but I’m hoping to still have a chance of setting a better example for my youngest 
children.”
Medication Assisted Treatment (MAT) Counselor - Chelsea Poland
◦ “We’re still learning about best practices for suboxone treatment. There are now state wide learning 
collaboratives where we can learn what is working well for other clinics in the state.”
MAT Nurse – Barb Wynes
◦ “MAT helps with all the other needs of the patient besides the medication. We also help with care 




A survey was developed to assess patient perspective on
◦ Rating of current treatment
◦ Suggested improvements 
◦ Opinion of signing a “medication contract”
◦ Barriers in current treatment
◦ Whether they receive external counseling
◦ Interest level in group therapy options
Provide feedback to MAT staff and provider on results of survey, and facilitate discussion of 
potential adjustments to increase retention and decrease amount of relapses occurring. 
5
Results
31 surveys were collected with a wide range of suboxone patients medication adherence histories.
Overall rating of current treatment was a 4.5 out of 5 scale, with no patients rating current treatment at a 1 (very 
poor) or 2 (poor).
◦ Many patients cited the office was an open environment that they could discuss problems, and they enjoyed being able to 
have on site counseling.
71% of patients had “No opinion” of pain contract, and 29% “find it helpful”
Common suggestions for improvement included 
◦ Less of a wait time
◦ Wanted provider to listen to them better
Many patients cited having the availability of MAT staff and their doctor was very helpful in their treatment.
The most common barrier to treatment was difficulty with transportation.
48% of patients have counseling outside of MAT.
The group that received the greatest amount of interest was Smoking Cessation.
6
Limitations and Effectiveness
The sample was less than 50% of the current suboxone patient population at Northern Green 
Mountain Family Practice
Patient attitudes and adherence to MAT widely range from being compliant for years to having 
illicit drug use during the week
◦ Number of visit is dependent upon adherence. Can range from having to visit 1 time per week to once 
every 4 weeks
◦ While we did not evaluate patients current treatment schedule, it was known subjectively to heavily 
influence outlook on treatment.
7
Recommendations
Addressing the long wait time patients experience at medical visits, this will hopefully resolve 
once another provider at the office becomes certified to prescribe suboxone.
Further assessment of group therapy, including how often people would be able to attend. MAT 
staff is open to including a new group session if enough interest occurs.
Repeat survey after St. Albans opens new hub for methadone treatment. 
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